As a proof-of-concept, we decided to target ER/PI3K interactions using an anti-estrogen (fulvestrant) or a PI3K inhibitor alone (BYL719) or in combination in 6 models of ER+ and 3 ER BC PDXs. Here, PIK3CA is linked to breast cancer.